17th International AIDS Conference Mexico City, Mexico - August 13 - 18, 2008

VIROLOGIC OUTCOMES OF THE ADULT AIDS PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN CHINA

Int Conf AIDS. 2008 Aug 13-18;17 Abstract No. MOAB0205

Y. Ma, D. Zhao, L. Yu, Y. Zhao, Z. Dou, F. Zhang
Chinese Center for Disease Control and Prevention, National Center for AIDS/STD Control & Prevention, Beijing, China

BACKGROUND: Free antiretroviral therapy has rapidly expanded in China within five years. As of June 2007, a total of 35557 patients nationwide have received ART, with 29184 still treated (82.1%). However, resource limitations prevent guaranteed viral load testing for all patients undergoing treatment. Cross-sectional evaluation of viral suppression results in Chinese ART patients establishes a scientific basis for assessing future resource needs.

METHODS: Cross-sectional survey used. PPS or simple stochastic sampling methods selected 24 counties from six primarily-FPD provinces and two primarily-IDU/sexual transmission provinces. Samples taken according to varying treatment durations, from which patients receiving treatment are then randomly selected; samples total 1200 persons. Viral load tests are completed for each patient sampled. Target for viral suppression is below LDL.

RESULTS: 1162 of 1200 eligible subjects included. Mean age 40.4, 55.7% male. Infection routes were 55.6% FPD, 24.5% sexual contact, 19.9% IDU/other. Proportion of patients achieving <LDL for 6, 12, and 24 months treated were 79.0%, 71.5%, and 65.0%, respectively (P<0.01). Within treatment duration groups, no differences in patients were found with respect to age or gender. Viral suppression was proportionately higher in patients taking the state-recommended first-line regimen-85.3%, 82.7%, and 82.5% for 6, 12, and 24 months ART, respectively-than for other regimens-57.1%, 41.1%, and 59.8% for 6, 12, and 24 months ART, respectively (P<0.01 for all groups).

CONCLUSIONS: In resource-limited settings, developing a cross-sectional study effectively monitors and evaluates national ART treatment outcomes. Drug variety was limited during the early stages of China’s ART projects. Although antiretroviral therapy has effectively lowered the fatality rate, concurrently about 30% of patients presently treated experience treatment failure. Following study results allows for evaluating ART patients experiencing treatment failure nationwide, projecting second-line treatment needs, and beginning necessary preparations.

Download PDF of this abstract.

2008-08-13
MOAB0205

Copyright © 2008 - International AIDS Society (IAS). All information and content relating to the abstracts from the 16th International AIDS Conference, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501c(3) not-for-profit organization made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, GlaxoSmithKline, the National Library of Medicine, Roche / Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.